Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…Подробнее

Addressing the major challenges to CAR-T therapy in AMLПодробнее

iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicineПодробнее

An update on CAR-T therapy in AML: challenges & emerging strategiesПодробнее

Challenges in developing CAR-T therapy for AMLПодробнее

The challenges of implementing CAR-T therapy in CLLПодробнее

The challenges of using CAR-T cell therapy to treat patients with CLLПодробнее

Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-TsПодробнее

Key challenges in developing CAR-T therapy for CLLПодробнее

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cellsПодробнее

Challenges in using CAR-T therapy & BTK inhibitors in patients with R/R MCLПодробнее

Challenges of CAR-T therapy for CLLПодробнее

Future prospects for CAR-T cell therapy in AMLПодробнее

Remaining challenges in treating ALL with CAR-T therapyПодробнее

Highlights from the immunotherapy in CLL sessionПодробнее

Challenges With CAR T-Cell Therapies in AMLПодробнее

CAR-T therapy in AML: why has there been a lack of success?Подробнее

Challenges in the clinical implementation of the CAR T-cell therapy A2B694Подробнее

Cellular therapies and their place in the CLL treatment landscapeПодробнее